Earnings call transcript: Jenoptik AG Q4 2025 beats EPS forecast, stock rises

Jenoptik beat Q4 EPS expectations (Q4 EPS €0.50 vs. €0.2705 consensus, +84.84% surprise) but Q4 revenue missed at €294.9m vs. €303.05m (-2.69%). Full-year 2025: revenue €1.05bn (-6% YoY), EPS €1.26 (down from €1.62), group EBITDA €193m (-13% YoY) and EBITDA margin 18.4% (-150bps). Management set FY2026 guidance of EPS €2.00 and revenue €1.311bn (with an EBITDA margin target 19–21%) and expects >80% backlog conversion; shares jumped ~3.6% post-release (latest trading +4.73%).

Analysis

Jenoptik’s recent operational moves — a new micro‑optics fab and a stronger mix toward inspection/biophotonics — create optionality rather than immediate linear earnings leverage. If high‑margin inspection and microlens sales grow to capture an incremental 5–10% of group revenues over 12–24 months, expect consolidated EBITDA expansion on the order of ~150–250 bps driven by higher gross margin and fixed‑cost absorption; conversely, any reversion to lithography‑weighted sales would erase that upside quickly.

Second‑order beneficiaries include precision tool and coating suppliers, test‑kit vendors for photonic ICs, and US service networks for mobility products — these vendors will see earlier and stickier order flow than broader semiconductor equipment suppliers because Jenoptik’s parts and service model frontloads recurring revenue. At the same time, legacy auto‑metrology exposure is the structural drag: weakness there magnifies cyclicality and keeps ROCE recovery hostage to non‑auto end‑market ramps.

Key catalysts to watch are (1) discrete restocking announcements from hyperscale/data‑center customers that would validate microlens demand over the next 3–9 months, (2) a material defense order (single‑quarter event) that would lift near‑term EBIT, and (3) refinancing costs and wage inflation trajectories over 6–12 months which can compress free cash flow if adverse. Tail risks: a renewed lithography capex pause or larger-than‑expected incremental wage settlements would reverse the positive re‑rating within a quarter.

From a valuation standpoint the market may be underpricing execution optionality in micro‑optics while overpricing durability of recent margin beats; that creates a defined window for asymmetric, time‑boxed trades that express the recovery in inspection and microlenses while protecting against cyclical reversals.

Key Decisions for Investors

• Buy JEN.DE (long equity) with a 12‑month target of +30–40% and a hard stop at -12% from entry — thesis: capture mix shift and Dresden fab optionality; risk: semi restart fails. Position size 3–5% of equity sleeve.
• Implement a hedge‑costed call spread to express upside while capping downside: buy 12‑month ATM call on JEN.DE and sell a 40–60% OTM call (choose strikes to roughly halve net premium). Expect 2.5–3x upside vs premium if operational mix improves; max loss = premium paid.
• Pair trade: long JEN.DE vs short CON.DE (Continental) 1:0.6 weight to neutralize euro‑industrial cyclic risk — rationale: isolates optics/biophotonics growth vs auto‑led metrology drag. Rebalance monthly, close if pair diverges >20%.
• Event hedge: buy inexpensive 3–6 month put protection (~6–8% OTM) ahead of key industry conf. windows (hyperscaler capex announcements) to guard against downside from semi demand disappointment; expected cost <1% of position value.